Effect of increase bowel motility with senokot on the predialysis serum potassium in maintenance hemodialysis patient

Phase 1

Completed

• Conditions: Maintenance hemodialysis patients with predialysis plasma potassium 5.1-6.0 mEq/L and adequate dialysis; Hyperkalemia; Hemodialysis; Senna glycoside; Bowel motility

• Registration Number: TCTR20210303001
• Lead Sponsor: /A

Brief Summary

Among ESRD on dialysis patients with hyperkalemia, Senna glycoside results in statistically significant decreases in plasma potassium level after 8 weeks of treatment. Senna glycoside is a safe and might be effective alternative for the treatment of hyperkalemia in ESRD.

Detailed Description

Not available

Study Timeline

• Study Completion: 2019-12-01
• Study Start: 2021-03-03
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 73

Inclusion Criteria

Age > 18 years
Trice weekly MHD at least 3 months with spKT/V > 1.2
Serum potassium 5.1-6.0 mEq/L
Informed consent

Exclusion Criteria

Hospitalization within 3 months
Significant intraabdominal or GI obstruction, infection, malignancy
Secondary cause of constipation or severe constipation

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
pre dialysis serum potassium (mid-week) 8 weeks mEq/

Secondary Outcome Measures

Name	Time	Method
serum potassium 8 weeks mEq/